{"transactions":[{"id":760229,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:23:38.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038961","document":"wk-form4_1780010616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038961/wk-form4_1780010616.xml","form_type":"4"}},{"id":760228,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:23:38.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":21333,"source":{"system":"sec-edgar","filing":"0001628280-26-038961","document":"wk-form4_1780010616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038961/wk-form4_1780010616.xml","form_type":"4"}},{"id":1104814,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":699800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.08,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":699800},"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104813,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":570868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.09,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":570868},"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104812,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.3,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104811,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":297186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":30.78,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":297186},"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104810,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":263750,"price":0.57,"value":150337.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104809,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":263750,"price":0.57,"value":150337.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104808,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":263750,"price":0.57,"value":150337.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104807,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":263750,"price":0.57,"value":150337.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1104806,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:37.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":10802138,"price":0.57,"value":6157218.66,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017836","document":"form4-06202025_040633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588925017836/form4-06202025_040633.xml","form_type":"4"}},{"id":1119706,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2025-06-07T00:26:07.000Z","date":"2025-06-06","kind":"other","planned":false,"acquired":true,"shares":10667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax planning purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member."}],"balance_after":10667,"source":{"system":"sec-edgar","filing":"0001628280-25-030078","document":"wk-form4_1749255960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030078/wk-form4_1749255960.xml","form_type":"4"}},{"id":1119705,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-07T00:26:07.000Z","date":"2025-06-06","kind":"other","planned":false,"acquired":false,"shares":10667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax planning purposes."}],"balance_after":13333,"source":{"system":"sec-edgar","filing":"0001628280-25-030078","document":"wk-form4_1749255960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030078/wk-form4_1749255960.xml","form_type":"4"}},{"id":1127697,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:17:24.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028888","document":"wk-form4_1748906238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028888/wk-form4_1748906238.xml","form_type":"4"}},{"id":1127696,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:17:24.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001628280-25-028888","document":"wk-form4_1748906238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028888/wk-form4_1748906238.xml","form_type":"4"}},{"id":1427453,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1427452,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":56.47,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12535},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1427451,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17550,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":24.49,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":17550},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1427450,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":9888},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1427449,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":22.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1427448,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:04:17.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001415889-24-021754","document":"form4-08202024_110813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924021754/form4-08202024_110813.xml","form_type":"4"}},{"id":1465610,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-07-02T00:27:32.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":204670,"price":1.2457,"value":254957.419,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average purchase price for the transaction reported was $1.2457 and the range of prices were between $1.18 and $1.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By the Revocable Inter Vivos Trust."}],"balance_after":10802138,"source":{"system":"sec-edgar","filing":"0001415889-24-018703","document":"form4-07022024_120728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924018703/form4-07022024_120728.xml","form_type":"4"}},{"id":1465609,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-07-02T00:27:32.000Z","date":"2024-06-27","kind":"purchase","planned":false,"acquired":true,"shares":410848,"price":1.1655,"value":478843.344,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $1.1655 and the range of prices were between $0.9899 and $1.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,811,004 shares previously held directly by the Reporting Person which were transferred to Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994 (the \"Revocable Inter Vivos Trust\") and are now owned indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By the Revocable Inter Vivos Trust."}],"balance_after":10597468,"source":{"system":"sec-edgar","filing":"0001415889-24-018703","document":"form4-07022024_120728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924018703/form4-07022024_120728.xml","form_type":"4"}},{"id":1481835,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-06-12T23:23:55.000Z","date":"2024-06-12","kind":"purchase","planned":false,"acquired":true,"shares":881913,"price":1.2428,"value":1096041.4764,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average purchase price for the transaction reported was $1.2428 and the range of prices were between $1.13 and $1.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":7375616,"source":{"system":"sec-edgar","filing":"0001415889-24-016563","document":"form4-06122024_110650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924016563/form4-06122024_110650.xml","form_type":"4"}},{"id":1481834,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-06-12T23:23:55.000Z","date":"2024-06-11","kind":"purchase","planned":false,"acquired":true,"shares":744308,"price":1.0944,"value":814570.6752,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average purchase price for the transaction reported was $1.0944, and the range of prices were between $0.9299 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":6493703,"source":{"system":"sec-edgar","filing":"0001415889-24-016563","document":"form4-06122024_110650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924016563/form4-06122024_110650.xml","form_type":"4"}},{"id":1481833,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-06-12T23:23:55.000Z","date":"2024-06-10","kind":"purchase","planned":false,"acquired":true,"shares":1378901,"price":0.8764,"value":1208468.8364,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $0.8764 and the range of prices were between $0.7392 and $0.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":5749395,"source":{"system":"sec-edgar","filing":"0001415889-24-016563","document":"form4-06122024_110650.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924016563/form4-06122024_110650.xml","form_type":"4"}},{"id":1489695,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:09:25.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":23168,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-015664","document":"form4-06052024_110622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924015664/form4-06052024_110622.xml","form_type":"4"}},{"id":1496719,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T18:40:54.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the stock option vest and become exercisable on the earlier of (i) May 29, 2025, or (i) the date of the Company's next annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":10.1,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-025997","document":"wk-form4_1717180847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024025997/wk-form4_1717180847.xml","form_type":"4"}},{"id":1496718,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T18:40:54.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on May 29, 2025, and the remaining shares vest in 24 equal monthly installments thereafter."}],"balance_after":16000,"derivative":{"exercise_price":10.1,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-025997","document":"wk-form4_1717180847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024025997/wk-form4_1717180847.xml","form_type":"4"}},{"id":1496717,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T18:40:54.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001628280-24-025997","document":"wk-form4_1717180847.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024025997/wk-form4_1717180847.xml","form_type":"4"}},{"id":1637855,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-17T01:34:27.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":699800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares vest in 48 equal monthly installments beginning on February 15, 2024."}],"balance_after":699800,"derivative":{"exercise_price":1.08,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":699800},"source":{"system":"sec-edgar","filing":"0001415889-24-004262","document":"form4-02172024_010220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924004262/form4-02172024_010220.xml","form_type":"4"}},{"id":1637854,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2024-02-17T01:34:27.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":270339,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2811004,"source":{"system":"sec-edgar","filing":"0001415889-24-004262","document":"form4-02172024_010220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000141588924004262/form4-02172024_010220.xml","form_type":"4"}},{"id":1736381,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-17T22:41:27.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":97935,"price":1.084,"value":106161.54,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average purchase price for the transaction reported was $1.084, and the range of prices were between $1.04 and $1.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":2540665,"source":{"system":"sec-edgar","filing":"0001209191-23-055826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919123055826/doc4.xml","form_type":"4"}},{"id":1736380,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-17T22:41:27.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":262433,"price":0.9965,"value":261514.4845,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $0.9965, and the range of prices were between $0.90 and $1.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":2442730,"source":{"system":"sec-edgar","filing":"0001209191-23-055826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919123055826/doc4.xml","form_type":"4"}},{"id":1736379,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-11-17T22:41:27.000Z","date":"2023-11-15","kind":"purchase","planned":false,"acquired":true,"shares":1370688,"price":0.8045,"value":1102718.496,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $0.8045, and the range of prices were between $0.765 and $0.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":2180297,"source":{"system":"sec-edgar","filing":"0001209191-23-055826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919123055826/doc4.xml","form_type":"4"}},{"id":1869323,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-02T23:08:28.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12535,"derivative":{"exercise_price":56.47,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12535},"source":{"system":"sec-edgar","filing":"0001209191-23-034044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919123034044/doc4.xml","form_type":"4"}},{"id":2007034,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-17T21:14:44.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":570868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant."}],"balance_after":570868,"derivative":{"exercise_price":2.09,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":570868},"source":{"system":"sec-edgar","filing":"0001209191-23-010559","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919123010559/doc4.xml","form_type":"4"}},{"id":2235660,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-10T23:00:15.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":17550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":17550,"derivative":{"exercise_price":24.49,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":17550},"source":{"system":"sec-edgar","filing":"0001209191-22-036112","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122036112/doc4.xml","form_type":"4"}},{"id":2263354,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-05-19T22:03:27.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":300000,"price":3.7817,"value":1134510.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average purchase price for the transaction reported was $3.7817, and the range of prices were between $3.54 and $4.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":809609,"source":{"system":"sec-edgar","filing":"0001209191-22-030688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122030688/doc4.xml","form_type":"4"}},{"id":2263353,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-05-19T22:03:27.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":206198,"price":3.7248,"value":768046.3104,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $3.7248, and the range of prices were between $3.60 and $4.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":509609,"source":{"system":"sec-edgar","filing":"0001209191-22-030688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122030688/doc4.xml","form_type":"4"}},{"id":2263352,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-05-19T22:03:27.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":90931,"price":3.8329,"value":348529.4299,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $3.8329, and the range of prices were between $3.70 and $3.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":303411,"source":{"system":"sec-edgar","filing":"0001209191-22-030688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122030688/doc4.xml","form_type":"4"}},{"id":2287766,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-04-29T20:03:43.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":9888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":9888,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":9888},"source":{"system":"sec-edgar","filing":"0001209191-22-026224","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122026224/doc4a.xml","form_type":"4/A","original_submission_date":"2021-06-17"}},{"id":2387953,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-17T22:25:28.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant."}],"balance_after":400000,"derivative":{"exercise_price":7.3,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-22-010910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919122010910/doc4.xml","form_type":"4"}},{"id":2480302,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-08T23:21:55.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":14356,"price":12.085,"value":173492.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $12.085, and the range of prices were between $11.83 and $12.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":212480,"source":{"system":"sec-edgar","filing":"0001209191-21-068594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919121068594/doc4.xml","form_type":"4"}},{"id":2663216,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2021-06-17T23:01:11.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12000,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-041667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919121041667/doc4.xml","form_type":"4"}},{"id":2948330,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-11T21:41:51.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":297186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant."}],"balance_after":297186,"derivative":{"exercise_price":30.78,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":297186},"source":{"system":"sec-edgar","filing":"0001209191-20-062953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120062953/doc4.xml","form_type":"4"}},{"id":2948329,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-11T21:41:51.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":198124,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":198124,"source":{"system":"sec-edgar","filing":"0001209191-20-062953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120062953/doc4.xml","form_type":"4"}},{"id":3004984,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":263750},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004983,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":263750},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004982,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":263750},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004981,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":263750},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004980,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Convertible Promissory Note","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"price":0,"reported_value":3000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":0,"derivative":{"exercise_price":16.15,"expiration_date":"2022-02-20","underlying":"Common Stock","underlying_shares":185758},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004979,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Preferred Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":1565475,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1651576},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004978,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":300001,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":316501},"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004977,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":263750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":263750,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004976,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":263750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":263750,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004975,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":263750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020."}],"balance_after":263750,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004974,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":263750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020."}],"balance_after":263750,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004973,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":95500,"price":19,"value":1814500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":4370496,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004972,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":185758,"price":16.15,"value":2999991.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":4274996,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004971,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":1651576,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":4089238,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3004970,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-16T19:29:25.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":316501,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994."}],"balance_after":2437662,"source":{"system":"sec-edgar","filing":"0001209191-20-055030","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120055030/doc4.xml","form_type":"4"}},{"id":3104112,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-19T22:12:25.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 18, 2021, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12000,"derivative":{"exercise_price":22.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-038042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190273/000120919120038042/doc4.xml","form_type":"4"}},{"id":418283,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-21","kind":"gift","acquired":true,"shares":9393,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares gifted to family trust."}],"balance_after":2317800,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":418282,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-21","kind":"gift","acquired":false,"shares":9393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares gifted to family trust."}],"balance_after":19602,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":418281,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-21","kind":"tax_withholding","acquired":false,"shares":7071,"price":80.69,"value":570558.99,"ownership":{"direct":true},"balance_after":28995,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":418280,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-21","kind":"grant","acquired":true,"shares":6805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":36066,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":418279,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-21","kind":"grant","acquired":true,"shares":16468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively."}],"balance_after":29261,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":418278,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2018-02-23T23:58:48.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":340,"price":62.3475,"value":21198.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan."}],"balance_after":12793,"source":{"system":"sec-edgar","filing":"0001127602-18-008140","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218008140/form4.xml","form_type":"4"}},{"id":419636,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2018-02-06T02:01:51.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":94360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested."}],"balance_after":94360,"derivative":{"exercise_price":83.49,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":94360},"source":{"system":"sec-edgar","filing":"0001127602-18-004173","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760218004173/form4.xml","form_type":"4"}},{"id":422047,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-11-22T00:04:33.000Z","date":"2017-11-20","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Gift of shares from family trust to charity."}],"balance_after":2308407,"source":{"system":"sec-edgar","filing":"0001127602-17-033091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217033091/form4.xml","form_type":"4"}},{"id":429886,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-16","kind":"gift","acquired":true,"shares":11558,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares gifted to family trust."}],"balance_after":2318407,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":429885,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-16","kind":"gift","acquired":false,"shares":11558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares gifted to family trust."}],"balance_after":12453,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":429884,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-16","kind":"tax_withholding","acquired":false,"shares":7070,"price":70.31,"value":497091.7,"ownership":{"direct":true},"balance_after":24011,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":429883,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":3021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2014. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":31081,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":429882,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":5773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2015, and February 1, 2016. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2017 and December 31, 2018, respectively."}],"balance_after":28060,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":429881,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2017-02-22T02:18:24.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":315,"price":59.33,"value":18688.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan."}],"balance_after":22287,"source":{"system":"sec-edgar","filing":"0001127602-17-007551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217007551/form4.xml","form_type":"4"}},{"id":430873,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2017-02-07T02:43:40.000Z","date":"2017-02-02","kind":"grant","acquired":true,"shares":104570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested."}],"balance_after":104570,"derivative":{"exercise_price":72.25,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":104570},"source":{"system":"sec-edgar","filing":"0001127602-17-004209","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760217004209/form4.xml","form_type":"4"}},{"id":433034,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-11-29T19:12:06.000Z","date":"2016-11-22","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Gift of shares from family trust to charity."}],"balance_after":2306849,"source":{"system":"sec-edgar","filing":"0001127602-16-068562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216068562/form4.xml","form_type":"4"}},{"id":435410,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-08-26T16:34:08.000Z","date":"2016-08-24","kind":"gift","acquired":false,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Gift of shares from family trust to charity."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares gifted to family trust on various dates between 2013 and 2016."}],"balance_after":2316849,"source":{"system":"sec-edgar","filing":"0001127602-16-061215","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216061215/form4.xml","form_type":"4"}},{"id":441890,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-02-19T00:52:20.000Z","date":"2016-02-16","kind":"tax_withholding","acquired":false,"shares":40716,"price":91.15,"value":3711263.4,"ownership":{"direct":true},"balance_after":191940,"source":{"system":"sec-edgar","filing":"0001127602-16-042270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216042270/form4.xml","form_type":"4"}},{"id":441889,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-02-19T00:52:20.000Z","date":"2016-02-16","kind":"grant","acquired":true,"shares":52914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":232656,"source":{"system":"sec-edgar","filing":"0001127602-16-042270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216042270/form4.xml","form_type":"4"}},{"id":441888,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-02-19T00:52:20.000Z","date":"2016-02-16","kind":"grant","acquired":true,"shares":14326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2014, and February 1, 2015. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2016, and committee certifications respectively."}],"balance_after":179742,"source":{"system":"sec-edgar","filing":"0001127602-16-042270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216042270/form4.xml","form_type":"4"}},{"id":441887,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"officer":true,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2016-02-19T00:52:20.000Z","date":"2016-02-15","kind":"grant","acquired":true,"shares":248,"price":76.024,"value":18853.952,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan."}],"balance_after":165416,"source":{"system":"sec-edgar","filing":"0001127602-16-042270","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000112760216042270/form4.xml","form_type":"4"}},{"id":442930,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-02-03T22:44:05.000Z","date":"2016-02-01","kind":"grant","acquired":true,"shares":85750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested."}],"balance_after":85750,"derivative":{"exercise_price":84.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":85750},"source":{"system":"sec-edgar","filing":"0001179110-16-018454","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911016018454/edgar.xml","form_type":"4"}},{"id":444256,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"exercise","acquired":false,"shares":43600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant.  The balance will vest 5% quarterly thereafter until fully vested."}],"balance_after":28800,"derivative":{"exercise_price":23.755,"expiration_date":"2020-01-28","underlying":"Common Stock","underlying_shares":43600},"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444255,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"exercise","acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested."}],"balance_after":211600,"derivative":{"exercise_price":19.085,"expiration_date":"2021-01-20","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444254,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"sale","acquired":false,"shares":39569,"price":102.221,"value":4044782.749,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices reported for the transactions reported here range from $101.46 to $102.45.  Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request"}],"balance_after":127936,"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444253,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"sale","acquired":false,"shares":30431,"price":102.6571,"value":3123958.2101,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices reported for the transactions reported here range from $102.46 to $102.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request."}],"balance_after":167505,"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444252,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"exercise","acquired":true,"shares":26400,"price":19.085,"value":503844.0,"ownership":{"direct":true},"balance_after":197936,"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444251,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-12-17T20:40:57.000Z","date":"2015-12-15","kind":"exercise","acquired":true,"shares":43600,"price":23.755,"value":1035718.0,"ownership":{"direct":true},"balance_after":171536,"source":{"system":"sec-edgar","filing":"0001179110-15-016421","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015016421/edgar.xml","form_type":"4"}},{"id":444999,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2015-11-18T17:32:18.000Z","date":"2015-11-16","kind":"exercise","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant.  The balance will vest 5% quarterly thereafter until fully vested."}],"balance_after":72400,"derivative":{"exercise_price":23.755,"expiration_date":"2020-01-28","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001179110-15-015043","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015015043/edgar.xml","form_type":"4"}},{"id":444998,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-11-18T17:32:18.000Z","date":"2015-11-16","kind":"sale","acquired":false,"shares":5544,"price":103.7871,"value":575395.6824,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices reported for the transactions reported here range from $103.74 to $103.9216. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request."}],"balance_after":165168,"source":{"system":"sec-edgar","filing":"0001179110-15-015043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015015043/edgar.xml","form_type":"4"}},{"id":444997,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-11-18T17:32:18.000Z","date":"2015-11-16","kind":"sale","acquired":false,"shares":18981,"price":103.2549,"value":1959881.2569,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices reported for the transactions reported here range from $102.74 to $103.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request."}],"balance_after":170712,"source":{"system":"sec-edgar","filing":"0001179110-15-015043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015015043/edgar.xml","form_type":"4"}},{"id":444996,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-11-18T17:32:18.000Z","date":"2015-11-16","kind":"sale","acquired":false,"shares":45475,"price":102.2571,"value":4650141.6225,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices reported for the transactions reported here range from $101.74 to $102.73.  Full information regarding the number of shares purchased or sold at each separate p2rice will be provided to the SEC, the issuer or its shareowners upon request"}],"balance_after":189693,"source":{"system":"sec-edgar","filing":"0001179110-15-015043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015015043/edgar.xml","form_type":"4"}},{"id":444995,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-11-18T17:32:18.000Z","date":"2015-11-16","kind":"exercise","acquired":true,"shares":70000,"price":23.755,"value":1662850.0,"ownership":{"direct":true},"balance_after":235168,"source":{"system":"sec-edgar","filing":"0001179110-15-015043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015015043/edgar.xml","form_type":"4"}},{"id":445093,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-11-13T18:01:09.000Z","date":"2015-11-03","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Gift of shares from family trust to charity."}],"balance_after":2149681,"source":{"system":"sec-edgar","filing":"0001179110-15-014830","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015014830/edgar.xml","form_type":"4"}},{"id":445810,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2015-10-16T21:32:59.000Z","date":"2015-10-15","kind":"exercise","acquired":false,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant.  The balance will vest 5% quarterly thereafter until fully vested."}],"balance_after":142400,"derivative":{"exercise_price":23.755,"expiration_date":"2020-01-28","underlying":"Common Stock","underlying_shares":1600},"source":{"system":"sec-edgar","filing":"0001179110-15-014072","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015014072/edgar.xml","form_type":"4"}},{"id":445809,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2015-10-16T21:32:59.000Z","date":"2015-10-15","kind":"exercise","acquired":false,"shares":68400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant.  The balance will vest 5% quarterly thereafter until fully vested."}],"balance_after":0,"derivative":{"exercise_price":23.6,"expiration_date":"2019-01-21","underlying":"Common Stock","underlying_shares":68400},"source":{"system":"sec-edgar","filing":"0001179110-15-014072","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015014072/edgar.xml","form_type":"4"}},{"id":445808,"issuer":{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock","published_at":"2015-10-16T21:32:59.000Z","date":"2015-10-15","kind":"sale","acquired":false,"shares":25319,"price":101.1789,"value":2561748.5691,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices reported for the transactions reported here range from $100.64 to $101.625. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request."}],"balance_after":165168,"source":{"system":"sec-edgar","filing":"0001179110-15-014072","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882095/000117911015014072/edgar.xml","form_type":"4"}}],"next_cursor":"2015-10-16T21:32:59.000000Z,445808"}